Ozempic under suspicion: FDA warned of the risk of sudden vision loss from popular weight-loss drugs

In certain cases, it can lead to sudden and irreversible vision loss. The FDA has required that the instructions for the drugs be supplemented with appropriate warnings.

Weight-loss drugs have become a true global medical phenomenon in recent years. Millions of people use them to control weight and treat diabetes. However, a new warning from the American regulator forces us to take a fresh look at the safety of this category of medicines.

We explain what FDA specialists discovered, which drugs came under scrutiny, and who should monitor their vision especially carefully.

What did the FDA find?

On November 9, 2026, the FDA published an official warning about a potential increased risk of developing a rare disease — nonarteritic anterior ischemic optic neuropathy (NAION).

This condition arises due to impaired blood supply to the anterior part of the optic nerve.

As a result, nerve fibers can be damaged, and vision can deteriorate sharply. In the most severe cases, the changes become irreversible.

The peculiarity of the disease is that vision loss often occurs suddenly and without pain. Some patients notice the problem immediately upon waking.

After analyzing clinical studies and observational data, the FDA decided to require manufacturers of the relevant drugs to add information about the potential risk to the warnings and precautions section.

Which popular drugs came under scrutiny?

The warning applies to a group of drugs that act on GLP-1 receptors.

Among the most well-known medicines:

• Ozempic — used to treat type 2 diabetes mellitus.
• Wegovy — used for weight reduction and control.
• Rybelsus — a tablet form of semaglutide.
• Mounjaro — a drug based on tirzepatide.
• Zepbound — a drug based on tirzepatide intended for weight control.

These medicines act on the mechanisms regulating appetite and blood sugar levels.

That is why they have become widespread among patients with diabetes and obesity.

It is important to understand: the FDA warns of a potential risk for the entire relevant group of drugs, but the volume of evidence for individual active substances differs.

How great is the risk of losing vision?

The most important question is how often the dangerous complication occurs.

The FDA analyzed 126 randomized clinical trials involving 134,253 people.

The results showed:

However, the absolute risk remains very low.

The FDA emphasizes that the data obtained indicate a possible increase in risk but do not prove that the drugs themselves caused the disease.

An additional analysis of real-world medical data also produced ambiguous results: no statistically significant increase in risk was found compared with one of the groups of diabetes drugs, whereas an increase was found when compared with another group.

How can you tell that vision is in danger?

Doctors draw attention to several symptoms that must not be ignored.

The following are considered especially dangerous:

• sudden deterioration of vision in one eye;
• the appearance of dark or blind spots;
• a feeling of fog before the eyes;
• loss of individual areas of the visual field;
• distortion of color perception;
• a sharp decrease in image clarity.

The main feature of NAION is the absence of pronounced pain. A person may discover that one eye has begun to see significantly worse, almost unexpectedly.

If such symptoms appear while taking weight-loss or diabetes drugs, it is necessary to seek medical help immediately and undergo an examination by an ophthalmologist.

In case of sudden vision loss, one must not wait for the condition to improve on its own.

Why do weight-loss drugs in particular raise questions?

The mechanism of the possible link between the drugs and optic nerve damage has not yet been definitively established.

Researchers are considering several directions for studying the problem, including the influence of metabolic changes, sugar levels, and blood supply factors.

At the same time, patients with type 2 diabetes mellitus already have an increased risk of vascular complications, including optic nerve diseases.

Known risk factors for NAION also include:

• high blood pressure;
• cardiovascular diseases;
• obstructive sleep apnea syndrome;
• kidney diseases;
• anemia;
• smoking;
• diabetes mellitus.

Therefore, it is quite difficult to establish exactly what role the drug plays and what role is played by concomitant diseases.

What will change now for manufacturers?

After publishing the warning, the FDA required manufacturers of the relevant drugs to update the instructions.

Information about the potential risk of NAION must now appear in the warnings and precautions section.

This means that doctors and patients will receive additional information about a possible complication when prescribing and using the drugs.

Such changes do not mean automatic withdrawal of the drugs from the market or a ban on their use.

The regulator takes into account not only potential risks but also the medical benefits of the drugs, which are used to treat diabetes, obesity, and reduce cardiovascular risks.

Should you stop taking Ozempic?

Despite alarming headlines, it is not recommended to cancel prescribed treatment on your own.

For some patients, GLP-1 drugs are important in controlling diabetes, obesity, and related complications.

Abrupt discontinuation of therapy without consulting a doctor can lead to worsening disease control.

If a person has been diagnosed with NAION, the FDA recommends discussing with the treating specialist whether the drug should be discontinued. The decision should take into account the individual risks and benefits of treatment.

In the absence of symptoms of sudden vision loss, one should not independently change the prescribed treatment regimen solely because of the published warning.

What does this mean for millions of people?

The Ozempic story shows how important it is to continue monitoring the safety of modern medicines even after they reach the market.

GLP-1 drugs have indeed become one of the most notable achievements of modern pharmacology in the treatment of diabetes and obesity.

But widespread use requires constant analysis of possible side effects.

The new FDA warning does not mean that every person taking Ozempic or Wegovy risks going blind. It concerns a rare complication whose probability, according to the regulator's assessment, may be somewhat higher with the use of these drugs.

The main conclusion: sudden deterioration of vision during treatment must not be ignored. Timely consultation with an ophthalmologist can be decisive.